Trevi Therapeutics (TRVI) Non-Current Deffered Revenue (2018 - 2021)
Trevi Therapeutics' quarterly Non-Current Deffered Revenue came in at $419000.0 in Q3 2021, up 43.99% year-on-year from $291000.0 in Q3 2020, and up 158.64% quarter-over-quarter from $162000.0 in Q2 2021.
Trevi Therapeutics has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $419000.0 in Q3 2021.
- For the quarter ending Q3 2021, Non-Current Deffered Revenue rose 43.99% year-over-year to $419000.0; the trailing twelve-month figure through Sep 2021 stood at $419000.0 (up 43.99% YoY), and the FY2020 full-year result was $284000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q3 2021 stood at $419000.0, up from $162000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $1.5 million in Q4 2018, with the low at $162000.0 in Q1 2021.
- Average Non-Current Deffered Revenue over 3 years is $445571.4, with a median of $284000.0 recorded in 2020.
- Peak annual rise in Non-Current Deffered Revenue reached 43.99% in 2021, while the deepest fall reached 39.33% in 2021.
- Tracing TRVI's Non-Current Deffered Revenue over 3 years: stood at $1.5 million in 2018, then plunged by 81.49% to $284000.0 in 2020, then jumped by 47.54% to $419000.0 in 2021.
- The last three Non-Current Deffered Revenue figures came in at $419000.0 (Q3 2021), $162000.0 (Q2 2021), and $162000.0 (Q1 2021), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 419,000.00 |
| Jun 30, 2021 | 162,000.00 |
| Mar 31, 2021 | 162,000.00 |
| Dec 31, 2020 | 284,000.00 |
| Sep 30, 2020 | 291,000.00 |
| Jun 30, 2020 | 267,000.00 |
| Dec 31, 2018 | 1.53 Mn |